{"id":20418,"date":"2026-07-31T10:32:51","date_gmt":"2026-07-31T10:32:51","guid":{"rendered":"https:\/\/woncaeurope2026.org\/sessions\/when-the-superficial-veins-speak-a-case-report-of-recurrent-superficial-thrombophlebitis\/"},"modified":"2026-07-31T10:32:51","modified_gmt":"2026-07-31T10:32:51","slug":"when-the-superficial-veins-speak-a-case-report-of-recurrent-superficial-thrombophlebitis","status":"publish","type":"wsa_session","link":"https:\/\/woncaeurope2026.org\/fr\/sessions\/when-the-superficial-veins-speak-a-case-report-of-recurrent-superficial-thrombophlebitis\/","title":{"rendered":"When the superficial veins speak: a case report of recurrent superficial thrombophlebitis"},"content":{"rendered":"<p>Superficial vein thrombosis (SVT) has regained its place among the venous thromboembolism (VTE) pathology, as a clinical entity, not a benign condition we once neglected. Current evidence demonstrates that SVT can be the initial manifestation of underlying thrombophilia, particularly in cases with recurrent presentation.We present the case of a 25-year-old female who consulted with left lower limb SVT. Initial management included 3-month anticoagulation and compression therapy. After 8 months, A recurrent SVT occurred, so a thrombophilia screening was performed,\u00a0revealing a\u00a0 Factor V Leiden homozygous mutation. These findings have indicated a long-term anticoagulation.This case presented SVT as the first and sole manifestation of homozygous Factor V Leiden mutation, highlighting the importance of thrombophilia screening in young patients with recurrent SVT and challenging the traditional view of SVT as a benign condition. Besides, it demonstrates the importance of long-term anticoagulation in a high-risk thrombophilic patient with direct oral\u00a0anticoagulation as an approved option.This case highlighted the importance of thrombophilia screening within young patients presenting with unexplained or recurrent SVT.\u00a0 The Homozygous Factor V Leiden mutation represents a severe thrombophilic state requiring aggressive management with Long-term anticoagulation. Future implications suggest updating guidelines for thrombophilia screening in recurrent SVT, individualizing anticoagulation strategies based on thrombophilia severity, and enhancing awareness about SVT as a potential indicator of severe thrombophilia.Activated Protein C Resistance (APC-R), primarily caused by the Factor V Leiden (FVL) mutation, creates a hypercoagulable state. Once considered benign, Superficial Vein Thrombosis (SVT) is now recognized as a significant manifestation of this thrombophilia, especially in recurrent cases. The VTE risk is linked to FVL zygosity, with homozygotes facing a 50-100 fold increased risk. Consequently, guidelines recommend thrombophilia screening for recurrent or idiopathic SVT. For high-risk patients, such as those with homozygous FVL, long-term anticoagulation is justified.SVT can represent the initial clinical manifestation of severe inherited thrombophilia. Appropriate evaluation and long-term management are crucial in high-risk patients, particularly those with homozygous Factor V Leiden mutation. This case underscores the importance of maintaining clinical suspicion for underlying thrombophilia in recurrent SVT and adopting individualized anticoagulation strategies based on thrombotic risk assessment.<\/p>\n","protected":false},"template":"","class_list":["post-20418","wsa_session","type-wsa_session","status-publish","hentry","description-off"],"_links":{"self":[{"href":"https:\/\/woncaeurope2026.org\/fr\/wp-json\/wp\/v2\/wsa_session\/20418","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/woncaeurope2026.org\/fr\/wp-json\/wp\/v2\/wsa_session"}],"about":[{"href":"https:\/\/woncaeurope2026.org\/fr\/wp-json\/wp\/v2\/types\/wsa_session"}],"wp:attachment":[{"href":"https:\/\/woncaeurope2026.org\/fr\/wp-json\/wp\/v2\/media?parent=20418"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}